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Do I really need to have that test? 
Understanding risk and making medical decisions in the age of TMI.
Gene Elizabeth Harkless, DNSc, APRN
Associate Professor of Nursing
Introduction
Even in the age of Too Much Information, the truth is that in health care we have less hard data for treatment effectiveness than most people 
believe. Often, predicting a serious problem with preci-
sion is beyond our science. So, when a clinician tests 
for a diagnosis or recommends a treatment, what may 
be lurking behind that decision? Is it evidence-based 
reasoning? Or, could it be market-based pressures, in-
grained ritual, or simply clinical ignorance?
Are you, the consumer, entering the health care visit 
with fear or hope fueled by the barrage of media pro-
claiming health threats and new, powerful treatments?  
How do you decide what to do?
Using skills and strategies based in health literacy 
may help bring sanity to this confusing onslaught of 
information. The clinician and the consumer both need 
a healthy dose of skepticism, the ability to discrimi-
nate among information sources, and mastery of a few 
simple numerical concepts. Even for healthy young 
people, the use of these skills and strategies can help 
cut through the hype and provide evidence to consider 
when deciding to seek care, participate in screening 
tests, or consider using a medication.
But, is our health care system set up to support and 
encourage expanded health literacy? What may be the 
drawbacks of promoting a more activated, informed 
consumer? And, lastly, as we become better at discrimi-
nating overload information and hype from the essen-
tial and important particulars in health care informa-
tion, will we achieve health outcomes that matter?
Is treatment always needed?
Think about why you go to the “doctor.” (Because I am a family nurse practitioner, I choose to use the 
more inclusive term “clinician” in place of “doctor” as 
clinician includes many different primary care providers 
including nurse practitioners, nurse-midwives, physician 
assistants, and physicians.) Perhaps you were first taken 
to the clinician for an acute care visit because an earache 
complicated an otherwise mild illness. Your parents be-
lieved any ear infection to be dangerous, requiring im-
mediate treatment with antibiotics to avoid short-term 
severe illness and long-term hearing complications.
Today, we know that is not so. Ear infections in young 
healthy children over age two with mild to moderate 
symptoms are best managed with a watch-and-wait 
approach that delays any use of antibiotics for 48 to 72 
hours.1 By this time most children will not need antibi-
otics. At 24 hours, 61% of children have decreased symp-
toms whether they receive a placebo or an antibiotic.
To understand this better, a concept called “number 
needed to treat” helps us figure out how much added 
benefit a drug or other treatment provides beyond what 
would improve if you just waited for time to pass. 
For children with ear infections, because at least two-
thirds (or maybe as high as 90%) improve without an-
tibiotics, many children would have to be treated with 
antibiotics to help the few who may benefit. That the 
number needed to treat for this problem is more than 7 
(and may be as high as 20), means you have to treat at 
least 7 children who would get better on their own to 
improve the outcome of just 1 child, who would need an 
antibiotic to improve.
So, the outcome for just about all of the children 
given early antibiotics was not improved by the giv-
ing of antibiotics, because they were going to get better 
without any treatment. And, it means that each child 
not benefiting from an antibiotic was exposed to the 
risk of an allergic reaction, and that parents and/or the 
health care system incurred a significant amount of cost 
involved in obtaining that antibiotic.
Our science does not yet help us identify which 1 of 
the 7 to 20 children will benefit from early antibiotic 
treatment and for this we may need better diagnostic 
discriminators. Perhaps this information is hidden in 
our genome (stay tuned for those developments). But for 
now, medicine has recognized the unintended conse-
quences of over-treatment, including problems such as 
antibiotic resistance and increased cost of care.
Acute ear infection is just one condition, among 
many common ailments, including acute low back pain 
that, based on current evidence, indicate overly aggres-
sive use of medical treatment. Is this also the case for 
disease screening?
TMI: Decision Making in the Age of Information Overload
New evidence, major changes in cancer screening
Even beyond our inability to say precisely what treat-ments are truly effective and who will benefit from 
these treatments, we have great imprecision in our di-
agnostic and screening processes. If you are female, you 
are well aware of how many “health screening” actions 
you are expected to participate in, including those for 
breast and cervical cancer. If you are male, you prob-
ably visit clinicians for care far less often. Data from as 
recently as 2006 showed that young men between the 
ages of 20–29 years of age had less than one quarter the 
rate of visits for preventive care compared with young 
women. Female visits for Pap smears account for half 
of this difference.2 For these reasons, the examples here 
will focus on cancer screening for young women.
For decades, young women have been taught that 
breast cancer is deadly and must be diagnosed early to 
save lives. Women of all ages were expected to conduct 
monthly breast self-exams. Boys, not to be excluded 
from monthly search-and-find missions, were taught 
testicular self-exam, which is another unsupported 
intervention.2, 3 During the “annual physical exam (an-
other clinical service that has been found lacking in its 
effectiveness)” 4-6 young women from puberty onward 
were exhorted to continue breast self-exams and the 
skill was reinforced each visit. Finally, in 2009, the U.S 
Preventive Services Task Force (USPSTF), an indepen-
dent panel of experts, systematically reviewed breast 
cancer screening research. Their analysis and recom-
mendations exploded our old rituals of care .7
Relying on high-quality, large clinical trials that 
found breast self-exams resulted in high rates of referral 
for suspicious masses with no evidence of lives saved, 
the USPSTF graded the evidence for breast self-exams 
as “D.”7 A “D” grade means that there is moderate or 
high certainty that the service has no net benefit or that 
the harms outweigh the benefits and that the practice 
should be discouraged. Now, in contrast to preceding 
decades of clinical and social marketing messages pow-
erfully reinforcing the importance for breast self-exam 
(and, in more than a few cases, women feeling guilty for 
not practicing this “health-saving” practice), breast self-
exam is now out of favor.
Clearly, medicine is learning more and more that 
“the extent to which beliefs are based on evidence are 
very much less than believers suppose.”8 Similarly for 
the clinical breast exam, the “C” grade assigned by the 
USPSTF means that the net benefit is small and that the 
service should not be routinely provided, especially in 
women under age 40.7
Young women are also encouraged to be screened 
for cervical cancer. Wrongly, in my opinion. Too many 
clinicians continue to require cervical cancer screening 
as a mandatory prerequisite to prescribing contracep-
tion. It makes no sense to link pregnancy prevention to 
participation in a cancer prevention program. But over 
many decades, women have been held hostage to this 
ridiculous linkage—no Pap test, no contraceptives.  
The Pap test takes cells from the transformation zone 
of the cervix, which is the junction where cervical dys-
plasias (abnormal cells) arise. Out of those abnormal 
cells, rarely, and more often if HPV types 16 and 18 
are present, cervical cancer may develop. (Note: the 
HPV vaccine is safe and effective at protecting against 
these types.) Putting this into perspective, each year 
2 to 3 million Pap tests are interpreted as abnormal. 
Out of those, less than one half of one percent (0.5%), 
or 100,000 to 150,000, are high-grade dysplasia and of 
those high-grade lesions, there is a less than a 15% rate 
of progression to invasive cervical cancer over about 5 
to 15 years.9 Over 70% (at least 10,500 out of the 15,000) 
of those cases are related to HPV type 16 and 18.10
With our current understanding of the natural pro-
gression and resolution of low-grade cell changes of the 
cervix, it is now recommended that young women not 
be tested for cervical cancer before the age of 21. After 
age 21, a less than annual testing schedule, often every 
three years, is recommended for most women.9 This less 
aggressive approach prevents unnecessary interventions 
for mild abnormalities that will revert back to normal 
on their own while preserving the important benefits 
of cancer screening. This new, less aggressive approach 
earned an “A” grade by the USPSTF.9
But, in spite of the best evidence, when clinicians 
were surveyed recently, less than 25% followed the new 
recommendations, and most chose screening options 
that overused services.11
One other USPSTF “A” grade screening recommen-
dation is testing for chlamydia infection in sexually ac-
tive women age 24 or younger. Chlamydia trachomatis 
infects three million new people each year in the U.S. 
and it is a major cause of infertility, pelvic inflammatory 
disease, and tubal (ectopic) pregnancy in women. Most 
infected women have no symptoms. Therefore, screen-
ing using a nucleic amplification test has the potential 
to uncover hidden infections. Treatment can then be 
given to those who test positive. This will minimize the 
spread of the infection and decrease the risk of compli-
cations, improving the overall health of this young adult 
population.  However, even though chlamydia screening 
received an “A” rating and the test is very good at identi-
fying those infected, the test is not perfect. How so?
The evidence is clear that nucleic amplification tests 
have test sensitivities of up to 97%.12 This means that 
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if 30 out of every 1,000 sexually active young women 
between the ages of 15 and 24 are expected to have chla-
mydia, the nucleic amplification test will correctly iden-
tify 29 of these women (30 x .97 = 29). One woman will 
be told she does not have chlamydia when she actually 
has the infection. That is called a false negative and nei-
ther false negatives nor false positives are medical errors 
but simply the nature of imperfect tests.  
The specificities of the nucleic amplification tests are 
also high at about 99%.12 Of the 970 young women who 
are tested for chlamydia but are not expected to have the 
infection, the test will correctly identify 99% of those, 
or 960 women. But, 10 women may be told they have 
chlamydia when, in fact, they do not have the infection. 
Again, these false positives are because the test is not 
perfect, not because of medical error. And, very impor-
tantly, samples obtained by urine tests are as reliable 
as cervical swabs.12 Hence, screening for this sexually 
transmitted disease can be done easily, although not as 
perfectly as many would like to believe. 
Conclusion
After working through the evidence that clarifies the reasoning behind the treatment and screening of 
a few conditions, I hope I’ve imparted a healthy skepti-
cism about current practices. And, I’ve underscored 
what abilities are required to discriminate evidence 
from values and beliefs. I want to leave you with a few 
high-quality, evidence-based resources that promote 
health literacy.
Becoming an informed, activated health care con-
sumer is now up to you. For future conversations, the 
following questions remain: What may be the draw-
backs of promoting a more activated, informed con-
sumer? And, lastly, as we become better at discriminat-
ing overload information and hype from the essential 
and important particulars in health care information, 
will we achieve health outcomes that matter?
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